A federal judge in Delaware has ordered AbbVie Inc. to turn over documents related to Boehringer Ingelheim’s defense of unclean hands in a case accusing the German drugmaker of infringing 74 patents with a biosimilar version of AbbVie’s immunosuppressant Humira.
The ruling, from U.S. Magistrate Judge Richard A. Lloret, came in response to Boehringer’s second set of production requests in the 10-month-old suit. Last August, AbbVie accused Boehringer of using dozens of its patents to capitalize on the clinical success of Humira, which has been approved to treat 10 different diseases, including various types of arthritis and Crohn’s disease.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]